Byetta (active ingredient: exenatide synthetic) subcutaneous injection
A 2023 preclinical study published in Nature Metabolism demonstrated that GLP-1 receptor activation suppressed reward-seeking behavior in animal models exposed to both food and alcohol cues
If approved, retatrutide could offer a powerful new option for individuals and healthcare providers seeking more effective solutions for severe obesity and its associated health risks
Regular follow-up appointments allow healthcare providers to assess treatment tolerance, adjust therapy as needed, and ensure that gastrointestinal symptoms are not masking other medical conditions
"It is noteworthy that GLP-1 drugs for diabetes became available in 2007 and long-term records of these drugs haven't shown any increased signs of adversity, apart from nausea and constipation or diarrhoea in about 5 to 10 per cent of people and an increased risk of gallstones." Some of the more serious concerns around semaglutide are linked to pancreatitis, acute kidney injury and anxiety
Injections can also cause swelling and bruising, and misuse can raise infection risk